{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:07:32Z","timestamp":1791925652886,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T00:00:00Z","timestamp":1511395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T00:00:00Z","timestamp":1511395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis C virus (HCV) is one of the leading causes of liver diseases and transplantation worldwide. The current available therapy for HCV infection is based on interferon-\u03b1, ribavirin and the new direct-acting antivirals (DAAs), such as NS3 protease and NS5B polymerase inhibitors. However, the high costs of drug design, severe side effects and HCV resistance presented by the existing treatments demonstrate the need for developing more efficient anti-HCV agents. This study aimed to evaluate the antiviral effects of sorbifolin (<jats:bold>1<\/jats:bold>) and pedalitin (<jats:bold>2<\/jats:bold>), two flavonoids from<jats:italic>Pterogyne nitens<\/jats:italic>on the HCV replication cycle. These compounds were investigated for their anti-HCV activities using genotype 2a JFH-1 subgenomic replicons and infectious virus systems. Flavonoids<jats:bold>1<\/jats:bold>and<jats:bold>2<\/jats:bold>inhibited virus entry up to 45.0% and 78.7% respectively at non-cytotoxic concentrations. The mechanism of the flavonoid<jats:bold>2<\/jats:bold>block to virus entry was demonstrated to be by both the direct action on virus particles and the interference on the host cells. Alternatively, the flavonoid<jats:bold>1<\/jats:bold>activity was restricted to its virucidal effect. Additionally, no inhibitory effects on HCV replication and release were observed by treating cells with these flavonoids. These data are the first description of<jats:bold>1<\/jats:bold>and<jats:bold>2<\/jats:bold>possessing<jats:italic>in vitro<\/jats:italic>anti-HCV activity.<\/jats:p>","DOI":"10.1038\/s41598-017-16336-y","type":"journal-article","created":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T11:07:32Z","timestamp":1510916852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Flavonoids from Pterogyne nitens Inhibit Hepatitis C Virus Entry"],"prefix":"10.1038","volume":"7","author":[{"given":"Jacqueline Farinha","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Sprengel","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina Machado","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia","family":"Bittar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Nogueira","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Nazar\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Roberto","family":"Polaquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Zothner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9821-1003","authenticated-orcid":false,"given":"Mark","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Oct\u00e1vio","family":"Regasini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina Gomes","family":"Jardim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,23]]},"reference":[{"key":"16336_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"Q Choo","year":"1989","unstructured":"Choo, Q., Kuo, G., Weiner, A. & Overby, L. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (80-.). 244, 359\u2013362 (1989).","journal-title":"Science (80-.)."},{"key":"16336_CR2","unstructured":"World Health Organisation. WHO | Hepatitis C. WHO (2016). Available at: http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/. (Accessed: 14th February 2017)."},{"key":"16336_CR3","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/hep.20819","volume":"42","author":"P Simmonds","year":"2005","unstructured":"Simmonds, P. et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962\u2013973 (2005).","journal-title":"Hepatology"},{"key":"16336_CR4","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMcp1006613","volume":"364","author":"HR Rosen","year":"2011","unstructured":"Rosen, H. R. Chronic Hepatitis C Infection. N. Engl. J. Med. 364, 2429\u20132438 (2011).","journal-title":"N. Engl. J. Med."},{"key":"16336_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/DHPS.S43304","volume":"6","author":"J Gaetano","year":"2014","unstructured":"Gaetano, J. Benefit\u2013risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Drug. Healthc. Patient Saf. 6, 37 (2014).","journal-title":"Drug. Healthc. Patient Saf."},{"key":"16336_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14218\/JCTH.2014.00041","volume":"3","author":"T Mcquaid","year":"2015","unstructured":"Mcquaid, T., Savini, C. & Seyedkazemi, S. Sofosbuvir, a Significant Paradigm Change in HCV Treatment. J. Clin. Transl. Hepatol. 3, 27\u201335 (2015).","journal-title":"J. Clin. Transl. Hepatol."},{"key":"16336_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1086\/595848","volume":"48","author":"V Soriano","year":"2009","unstructured":"Soriano, V., Peters, M. G. & Zeuzem, S. New Therapies for Hepatitis C Virus Infection. Clin. Infect. Dis. 48, 313\u2013320 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"16336_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","volume":"13","author":"E Lawitz","year":"2013","unstructured":"Lawitz, E. et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect. Dis. 13, 401\u2013408 (2013).","journal-title":"Lancet Infect. Dis."},{"key":"16336_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.4254\/wjh.v7.i5.725","volume":"7","author":"H Barth","year":"2015","unstructured":"Barth, H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J. Hepatol. 7, 725 (2015).","journal-title":"World J. Hepatol."},{"key":"16336_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.antiviral.2014.05.015","volume":"108","author":"E Poveda","year":"2014","unstructured":"Poveda, E. et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 108, 181\u2013191 (2014).","journal-title":"Antiviral Res."},{"key":"16336_CR11","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1093\/infdis\/jis761","volume":"207","author":"DL Wyles","year":"2013","unstructured":"Wyles, D. L. Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy. J. Infect. Dis. 207, S33\u2013S39 (2013).","journal-title":"J. Infect. Dis."},{"key":"16336_CR12","doi-asserted-by":"publisher","unstructured":"Brahmachari, G. in Bioactive Natural Products 1\u2013199 https:\/\/doi.org\/10.1142\/9789814335386_0001. (WORLD SCIENTIFIC, 2011).","DOI":"10.1142\/9789814335386_0001"},{"key":"16336_CR13","doi-asserted-by":"publisher","unstructured":"Dixon, R. A., Dey, P. M. & Lamb, C. J. In (ed. Meister, A.) 1\u2013136 (John Wiley & Sons, Inc., 2006). https:\/\/doi.org\/10.1002\/9780470123010.ch1.","DOI":"10.1002\/9780470123010.ch1"},{"key":"16336_CR14","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1021\/jf901128u","volume":"57","author":"H-Y Ho","year":"2009","unstructured":"Ho, H.-Y., Cheng, M.-L., Weng, S.-F., Leu, Y.-L. & Chiu, D. T.-Y. Antiviral Effect of Epigallocatechin Gallate on Enterovirus 71. J. Agric. Food Chem. 57, 6140\u20136147 (2009).","journal-title":"J. Agric. Food Chem."},{"key":"16336_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2014.11.001","volume":"113","author":"C Weber","year":"2015","unstructured":"Weber, C., Sliva, K., von Rhein, C., K\u00fcmmerer, B. M. & Schnierle, B. S. The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection. Antiviral Res. 113, 1\u20133 (2015).","journal-title":"Antiviral Res."},{"key":"16336_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/hep.24803","volume":"55","author":"N Calland","year":"2012","unstructured":"Calland, N. et al. (\u2212)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Hepatology 55, 720\u20139 (2012).","journal-title":"Hepatology"},{"key":"16336_CR17","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/BF02978215","volume":"28","author":"S-Y Lyu","year":"2005","unstructured":"Lyu, S.-Y., Rhim, J.-Y. & Park, W.-B. Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro. Arch. Pharm. Res. 28, 1293\u20131301 (2005).","journal-title":"Arch. Pharm. Res."},{"key":"16336_CR18","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jhep.2011.02.011","volume":"55","author":"J Goldwasser","year":"2011","unstructured":"Goldwasser, J. et al. Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J. Hepatol. 55, 963\u2013971 (2011).","journal-title":"J. Hepatol."},{"key":"16336_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1053\/j.gastro.2012.03.036","volume":"143","author":"S Haid","year":"2012","unstructured":"Haid, S. et al. A Plant-Derived Flavonoid Inhibits Entry of All HCV Genotypes Into Human Hepatocytes. Gastroenterology 143, 213\u2013222.e5 (2012).","journal-title":"Gastroenterology"},{"key":"16336_CR20","first-page":"1866","volume":"15","author":"J Blaising","year":"2013","unstructured":"Blaising, J. et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell. Microbiol. 15, 1866\u201382 (2013).","journal-title":"Cell. Microbiol."},{"key":"16336_CR21","unstructured":"Burkart, A. Las Leguminosas Argentinas. Buenos Aires Aem\u00e9 Agency (1952)."},{"key":"16336_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1746-4269-3-2","volume":"3","author":"M Crivos","year":"2007","unstructured":"Crivos, M. et al. Pathways as \u2018signatures in landscape\u2019: towards an ethnography of mobility among the Mbya-Guaran\u00ed (Northeastern Argentina). J. Ethnobiol. Ethnomed. 3, 2 (2007).","journal-title":"J. Ethnobiol. Ethnomed."},{"key":"16336_CR23","first-page":"249","volume":"25","author":"K Satake","year":"2015","unstructured":"Satake, K. et al. Human ABCB1 confers cells resistance to cytotoxic guanidine alkaloids from Pterogyne nitens. Biomed. Mater. Eng. 25, 249\u2013256 (2015).","journal-title":"Biomed. Mater. Eng."},{"key":"16336_CR24","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4067\/S0717-97072009000300004","volume":"54","author":"LO REGASINI","year":"2009","unstructured":"REGASINI, L. O. et al. Identification of triterpenes and sterols from Pterogyne nitens (fabaceae-caesalpinioideae) using high-resolution gas chromatography. J. Chil. Chem. Soc. 54, 218\u2013221 (2009).","journal-title":"J. Chil. Chem. Soc."},{"key":"16336_CR25","first-page":"4609","volume":"7","author":"LO Regasini","year":"2008","unstructured":"Regasini, L. O. et al. Free radical scavenging activity of Pterogyne nitens Tul. (Fabaceae). African J. Biotechnol. 7, 4609\u20134613 (2008).","journal-title":"African J. Biotechnol."},{"key":"16336_CR26","first-page":"335","volume":"28","author":"LO Regasini","year":"2007","unstructured":"Regasini, L. O. et al. Antiproliferative effect of Pterogyne nitens on melanoma cells. Rev. Ciencias Farm. Basica e Apl. 28, 335\u2013340 (2007).","journal-title":"Rev. Ciencias Farm. Basica e Apl."},{"key":"16336_CR27","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/j.phytochem.2008.01.006","volume":"69","author":"LO Regasini","year":"2008","unstructured":"Regasini, L. O. et al. Flavonols from Pterogyne nitens and their evaluation as myeloperoxidase inhibitors. Phytochemistry 69, 1739\u20131744 (2008).","journal-title":"Phytochemistry"},{"key":"16336_CR28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1248\/cpb.56.723","volume":"56","author":"DC Fernandes","year":"2008","unstructured":"Fernandes, D. C. et al. Myeloperoxidase Inhibitory and Radical Scavenging Activities of Flavones from Pterogyne nitens. Chem. Pharm. Bull. (Tokyo). 56, 723\u2013726 (2008).","journal-title":"Chem. Pharm. Bull. (Tokyo)."},{"key":"16336_CR29","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1590\/S0100-40422008000400018","volume":"31","author":"LO Regasini","year":"2008","unstructured":"Regasini, L. O. et al. Constituintes qu\u00edmicos das flores de Pterogyne nitens (Caesalpinioideae). Quim. Nova 31, 802\u2013806 (2008).","journal-title":"Quim. Nova"},{"key":"16336_CR30","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1590\/S1516-05722012000400014","volume":"14","author":"H Pasquini-Netto","year":"2012","unstructured":"Pasquini-Netto, H. et al. Avalia\u00e7\u00e3o das atividades antioxidante, anti e pr\u00f3-hemol\u00edtica do extrato etan\u00f3lico das folhas de pterogyne nitens Tul. (Fabaceae-Caesalpinioideae). Rev. Bras. Plantas Med. 14, 666\u2013672 (2012).","journal-title":"Rev. Bras. Plantas Med."},{"key":"16336_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1590\/S0100-46702011000200001","volume":"36","author":"JCR Vellosa","year":"2011","unstructured":"Vellosa, J. C. R. et al. Antioxidant and cytotoxic studies for kaempferol, quercetin and isoquercitrin. Eclet. Quim. 36, 7\u201320 (2011).","journal-title":"Eclet. Quim."},{"key":"16336_CR32","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1007\/s12272-014-0487-1","volume":"38","author":"JCR Vellosa","year":"2015","unstructured":"Vellosa, J. C. R. et al. Preliminary in vitro and ex vivo evaluation of afzelin, kaempferitrin and pterogynoside action over free radicals and reactive oxygen species. Arch. Pharm. Res. 38, 1168\u20131177 (2015).","journal-title":"Arch. Pharm. Res."},{"key":"16336_CR33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.apjtb.2016.08.003","volume":"6","author":"CS Lima","year":"2016","unstructured":"Lima, C. S. et al. Anti-Candida and anti-Cryptococcus evaluation of 15 non-alkaloidal compounds from Pterogyne nitens. Asian Pac. J. Trop. Biomed. 6, 841\u2013845 (2016).","journal-title":"Asian Pac. J. Trop. Biomed."},{"key":"16336_CR34","doi-asserted-by":"publisher","first-page":"8234","DOI":"10.1073\/pnas.90.17.8234","volume":"90","author":"J Bukh","year":"1993","unstructured":"Bukh, J., Purcell, R. H. & Miller, R. H. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. Proc. Natl. Acad. Sci. USA 90, 8234\u20138 (1993).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"16336_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.virol.2014.05.024","volume":"462\u2013463","author":"C Shibata","year":"2014","unstructured":"Shibata, C. et al. The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels. Virology 462\u2013463, 42\u20138 (2014).","journal-title":"Virology"},{"key":"16336_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1055\/s-0033-1360172","volume":"80","author":"S Lou","year":"2013","unstructured":"Lou, S. et al. Inhibition of Hepatitis C Virus Replication In Vitro by Xanthohumol, A Natural Product Present in Hops. Planta Med. 80, 171\u2013176 (2013).","journal-title":"Planta Med."},{"key":"16336_CR37","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/hep.22197","volume":"47","author":"Y Nahmias","year":"2008","unstructured":"Nahmias, Y. et al. Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 47, 1437\u20131445 (2008).","journal-title":"Hepatology"},{"key":"16336_CR38","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1128\/AAC.01546-08","volume":"53","author":"DL Wyles","year":"2009","unstructured":"Wyles, D. L. et al. The Octadecyloxyethyl Ester of (S)-9-[3-Hydroxy-2-(Phosphonomethoxy) Propyl]Adenine Is a Potent and Selective Inhibitor of Hepatitis C Virus Replication in Genotype 1A, 1B, and 2A Replicons. Antimicrob. Agents Chemother. 53, 2660\u20132662 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"16336_CR39","doi-asserted-by":"publisher","first-page":"10053","DOI":"10.1128\/JVI.01473-15","volume":"89","author":"N Calland","year":"2015","unstructured":"Calland, N. et al. Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. J. Virol. 89, 10053\u201310063 (2015).","journal-title":"J. Virol."},{"key":"16336_CR40","first-page":"1153","volume":"44","author":"J Souza","year":"2004","unstructured":"Souza, J., Molfetta, F. A., Honorio, K. M., Santos, R. H. A. & DaSilva, A. B. F. A Study on the Antipicornavirus Activity of Flavonoid Compounds (Flavones) by Using Quantum Chemical and Chemometric Methods. J. Chem. Inf. Model. 44, 1153\u20131161 (2004).","journal-title":"J. Chem. Inf. Model."},{"key":"16336_CR41","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1080\/10715760400016105","volume":"38","author":"AG Erlejman","year":"2004","unstructured":"Erlejman, A. G., Verstraeten, S. V., Fraga, C. G. & Oteiza, P. I. The Interaction of Flavonoids with Membranes: Potential Determinant of Flavonoid Antioxidant Effects. Free Radic. Res. 38, 1311\u20131320 (2004).","journal-title":"Free Radic. Res."},{"key":"16336_CR42","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0955-2863(02)00208-5","volume":"13","author":"KE Heim","year":"2002","unstructured":"Heim, K. E., Tagliaferro, A. R. & Bobilya, D. J. Flavonoid antioxidants: Chemistry, metabolism and structure-activity relationships. Journal of Nutritional Biochemistry 13, 572\u2013584 (2002).","journal-title":"Journal of Nutritional Biochemistry"},{"key":"16336_CR43","doi-asserted-by":"crossref","first-page":"162750","DOI":"10.1155\/2013\/162750","volume":"2013","author":"S Kumar","year":"2013","unstructured":"Kumar, S. & Pandey, A. K. Chemistry and biological activities of flavonoids: an overview. ScientificWorldJournal. 2013, 162750 (2013).","journal-title":"ScientificWorldJournal."},{"key":"16336_CR44","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.cld.2015.06.002","volume":"19","author":"KR Chacko","year":"2015","unstructured":"Chacko, K. R. & Gaglio, P. J. Meet the Classes of Directly Acting Antiviral Agents. Strengths and Weaknesses. Clin. Liver Dis. 19, 605\u2013617 (2015).","journal-title":"Clin. Liver Dis."},{"key":"16336_CR45","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nrmicro1645","volume":"5","author":"D Moradpour","year":"2007","unstructured":"Moradpour, D., Penin, F. & Rice, C. M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5, 453\u2013463 (2007).","journal-title":"Nat. Rev. Microbiol."},{"key":"16336_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-61","volume":"13","author":"ACG Jardim","year":"2013","unstructured":"Jardim, A. C. G. et al. Analysis of HCV quasispecies dynamic under selective pressure of combined therapy. BMC Infect. Dis. 13, 61 (2013).","journal-title":"BMC Infect. Dis."},{"key":"16336_CR47","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.3748\/wjg.v20.i11.2902","volume":"20","author":"S Nakamoto","year":"2014","unstructured":"Nakamoto, S., Kanda, T., Wu, S., Shirasawa, H. & Yokosuka, O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J. Gastroenterol. 20, 2902\u20132912 (2014).","journal-title":"World J. Gastroenterol."},{"key":"16336_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2014.12.037","volume":"477","author":"H Ji","year":"2015","unstructured":"Ji, H. et al. Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 477, 1\u20139 (2015).","journal-title":"Virology"},{"key":"16336_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/srep16084","volume":"5","author":"R Hajj","year":"2015","unstructured":"Hajj, R. et al. Combination of acamprosate and baclofen as a promising therapeutic approach for Parkinson\u2019s disease. Sci. Rep. 5, 16084 (2015).","journal-title":"Sci. Rep."},{"key":"16336_CR50","first-page":"103","volume":"17","author":"C Lin","year":"2006","unstructured":"Lin, C., Huang, Y., Cheng, L., Sheu, S. & Chen, C. Bioactive flavonoids from Ruellia tuberosa. J Chin Med 17, 103\u2013109 (2006).","journal-title":"J Chin Med"},{"key":"16336_CR51","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0031-9422(97)01042-X","volume":"48","author":"F Zaidi","year":"1998","unstructured":"Zaidi, F., Voirin, B., Jay, M. & Viricel, M. R. Free flavonoid aglycones from leaves of mentha pulegium and mentha suaveolens (Labiatae). Phytochemistry 48, 991\u2013994 (1998).","journal-title":"Phytochemistry"},{"key":"16336_CR52","doi-asserted-by":"crossref","unstructured":"Agrawal, P. K., Bansal, M. C., Porter, L. J. & Foo, L. Y. In Studies in Inorganic Chemistry 39, 432\u2013496 (1989).","DOI":"10.1016\/B978-0-444-87449-8.50014-6"},{"key":"16336_CR53","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0031-9422(00)00235-1","volume":"55","author":"JB Harborne","year":"2000","unstructured":"Harborne, J. B. & Williams, C. A. Advances in flavonoid research since 1992. Phytochemistry 55, 481\u2013504 (2000).","journal-title":"Phytochemistry"},{"key":"16336_CR54","doi-asserted-by":"publisher","unstructured":"Test No. 117: Partition Coefficient (n-octanol\/water), HPLC Method. (OECD Publishing, 2004). https:\/\/doi.org\/10.1787\/9789264069824-en.","DOI":"10.1787\/9789264069824-en"},{"key":"16336_CR55","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/hep.24610","volume":"54","author":"S Ciesek","year":"2011","unstructured":"Ciesek, S. et al. The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry. Hepatology 54, 1947\u20131955 (2011).","journal-title":"Hepatology"},{"key":"16336_CR56","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","volume":"38","author":"K Watashi","year":"2003","unstructured":"Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M. & Shimotohno, K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38, 1282\u20138 (2003).","journal-title":"Hepatology"},{"key":"16336_CR57","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/hep.23281","volume":"50","author":"S Ciesek","year":"2009","unstructured":"Ciesek, S. et al. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology 50, 1638\u20131645 (2009).","journal-title":"Hepatology"},{"key":"16336_CR58","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791\u20136 (2005).","journal-title":"Nat. Med."},{"key":"16336_CR59","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1053\/j.gastro.2007.08.005","volume":"133","author":"JM Gottwein","year":"2007","unstructured":"Gottwein, J. M. et al. Robust Hepatitis C Genotype 3a Cell Culture Releasing Adapted Intergenotypic 3a\/2a (S52\/JFH1) Viruses. Gastroenterology 133, 1614\u20131626 (2007).","journal-title":"Gastroenterology"},{"key":"16336_CR60","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.antiviral.2014.12.018","volume":"115","author":"ACG Jardim","year":"2015","unstructured":"Jardim, A. C. G. et al. Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro. Antiviral Res. 115, 39\u201347 (2015).","journal-title":"Antiviral Res."},{"key":"16336_CR61","doi-asserted-by":"publisher","first-page":"17775","DOI":"10.1074\/jbc.M210900200","volume":"278","author":"A Macdonald","year":"2003","unstructured":"Macdonald, A. et al. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing Ras-ERK pathway signaling. J. Biol. Chem. 278, 17775\u201317784 (2003).","journal-title":"J. Biol. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16336-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16336-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16336-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T04:00:20Z","timestamp":1750996820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-16336-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,23]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["16336"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-16336-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,23]]},"assertion":[{"value":"17 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"16127"}}